Ever Supreme Bio Technology (6712) Stock Overview
Engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
6712 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Ever Supreme Bio Technology Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$134.50 |
| 52 Week High | NT$188.00 |
| 52 Week Low | NT$133.00 |
| Beta | 0.52 |
| 1 Month Change | -5.28% |
| 3 Month Change | -16.72% |
| 1 Year Change | -11.41% |
| 3 Year Change | -13.12% |
| 5 Year Change | -54.75% |
| Change since IPO | 116.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6712 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -4.6% | 2.2% | 3.8% |
| 1Y | -11.4% | 26.4% | 93.1% |
Return vs Industry: 6712 underperformed the TW Biotechs industry which returned 26.4% over the past year.
Return vs Market: 6712 underperformed the TW Market which returned 93.1% over the past year.
Price Volatility
| 6712 volatility | |
|---|---|
| 6712 Average Weekly Movement | 2.6% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in TW Market | 11.9% |
| 10% least volatile stocks in TW Market | 2.5% |
Stable Share Price: 6712 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6712's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | n/a | www.ever-supreme.com.tw |
Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. It operates in two segments: Cell Preparation Business and Other Operating Business segments. The company’s products include umbilical cord mesenchymal stem cells (UMC01), a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke.
Ever Supreme Bio Technology Co., Ltd Fundamentals Summary
| 6712 fundamental statistics | |
|---|---|
| Market cap | NT$12.04b |
| Earnings (TTM) | NT$429.43m |
| Revenue (TTM) | NT$1.02b |
Is 6712 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6712 income statement (TTM) | |
|---|---|
| Revenue | NT$1.02b |
| Cost of Revenue | NT$296.18m |
| Gross Profit | NT$721.33m |
| Other Expenses | NT$291.90m |
| Earnings | NT$429.43m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.90 |
| Gross Margin | 70.89% |
| Net Profit Margin | 42.20% |
| Debt/Equity Ratio | 0% |
How did 6712 perform over the long term?
See historical performance and comparisonDividends
Does 6712 pay a reliable dividends?
See 6712 dividend history and benchmarks| Ever Supreme Bio Technology dividend dates | |
|---|---|
| Ex Dividend Date | Apr 16 2026 |
| Dividend Pay Date | May 08 2026 |
| Days until Ex dividend | 8 days |
| Days until Dividend pay date | 14 days |
Does 6712 pay a reliable dividends?
See 6712 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/23 12:55 |
| End of Day Share Price | 2026/04/23 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ever Supreme Bio Technology Co., Ltd is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xiaowei Huang | Masterlink Securities Corp. |
| Xin Ying Jiang | Yuanta Research |